Liver International

Article	Citations
Liver injury during highly pathogenic human coronavirus infections	609
Comparison of MAFLD and NAFLD diagnostic criteria in real world	343
Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China	318
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	263
Pathophysiological mechanisms of liver injury in COVID‐19	254
COVID‐19 and liver disease	227
Clinical characteristics of non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study	210
Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations	206
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’	196
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review	150
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population	131
Targeting ferroptosis alleviates methionine‐choline deficient (MCD)‐diet induced NASH by suppressing liver lipotoxicity	126
Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis	120
Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience	108
The global epidemiology of hepatitis E virus infection: A systematic review and meta‐analysis	107
Changing epidemiology of hepatocellular carcinoma in Asia	98
Abnormal liver function tests predict transfer to intensive care unit and death in COVID‐19	94
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19	88
SARS‐CoV‐2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID‐19	85
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis	78
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis	75
Hepatic macrophages: Key players in the development and progression of liver fibrosis	74
Metabolic‐associated fatty liver disease is associated with severity of COVID‐19	72
Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis	71
The changing scenario of hepatocellular carcinoma in Italy: an update	66

Radiomics in liver diseases: Current progress and future opportunities	65
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts	62
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	60
Bilirubin levels in patients with mild and severe Covid‐19: A pooled analysis	60
Diet and exercise in NAFLD/NASH: Beyond the obvious	59
The NAFLD‐MAFLD debate: Eminence vs evidence	58
Hepatitis E: An update on One Health and clinical medicine	58
Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19	56
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	56
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia	50
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation	49
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib	48
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH	48
Cardiodynamic state is associated with systemic inflammation and fatal acute‐on‐chronic liver failure	45
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	45
Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group	45
Treatment and the prognosis of hepatocellular carcinoma in Asia	44
LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases	43
MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study	43
The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy	42
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis	42
Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study	42
Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China an	42
Potential implications of COVID‐19 in non‐alcoholic fatty liver disease	42
Bile acids associate with specific gut microbiota, low‐level alcohol consumption and liver fibrosis in patients with non‐alcoholic fatty liver disease	41
Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study	41
Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis	41
Immune‐related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors	41
Redefining fatty liver disease classification in 2020	40
Incidence, prevalence and mortality of autoimmune hepatitis in England 1997‐2015. A population‐based cohort study	39
A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction	38
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B	38
High‐protein diet more effectively reduces hepatic fat than low‐protein diet despite lower autophagy and FGF21 levels	38
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma	37
Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?	36
Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study	36
Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study	36
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease	36
Safety of direct oral anticoagulants in patients with advanced liver disease	35
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life	35
Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis	35
Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States	34
Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection	34
Optimization of hepatitis C virus screening strategies by birth cohort in Italy	34
Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives	34
Incidence and risk factors of drug‐induced liver injury	33
Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)	33
MAFLD vs NAFLD: Let the contest begin!	33
2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta‐analysis	33
Liver involvement in children with SARS‐COV‐2 infection: Two distinct clinical phenotypes caused by the same virus	33

HBV 2021: New therapeutic strategies against an old foe	32
2021 ISHEN guidelines on animal models of hepatic encephalopathy	32
New drugs for NASH	32
Association of genetic variations with NAFLD in lean individuals	32
Low‐GGT intrahepatic cholestasis associated with biallelic USP53 variants: Clinical, histological and ultrastructural characterization	32
Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD	32
Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients	32
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study	32
PNPLA3I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings	31
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives	31
Exploring the landscape of steatotic liver disease in the general US population	31
Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus	31
Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease	31
Lymphocyte‐C‐reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study	30
Cell‐type‐resolved proteomic analysis of the human liver	30
The amount of liver fat predicts mortality and development of type 2 diabetes in non‐alcoholic fatty liver disease	30
Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients	30
Acceptance and use of a smartphone application in cirrhosis	30
Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review	30
Role of fibroblast growth factor signalling in hepatic fibrosis	30
COVID‐19 and the liver: A 2021 update	30
GES: A validated simple score to predict the risk of HCC in patients with HCV‐GT4‐associated advanced liver fibrosis after oral antivirals	30
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma	29
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…	29
Management of NAFLD in primary care settings	29
From NAFLD to MAFLD: Nurse and allied health perspective	29
Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation	29
Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection	29
Machine‐learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection	28
Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury	28
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure	28
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	28
The association of sex steroid hormone concentrations with non‐alcoholic fatty liver disease and liver enzymes in US men	28
Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease	28
The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt	27
Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population	27
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia	27
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan	27
Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI	27
PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD	26
Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high‐risk patients	26
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis	26
The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria	26
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	26
Rodent models of cholestatic liver disease: A practical guide for translational research	26
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	26
Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma	26
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease	26
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip	26
Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study	25
Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension	25
Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?	25
Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma	25
Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence	25
Concordance between MAFLD and NAFLD diagnostic criteria in ‘real‐world’ data	25
Road to elimination of HCV: Clinical challenges in HCV management	25
Integrins as a drug target in liver fibrosis	25
Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar	25
Nationwide treatment and outcomes of perihilar cholangiocarcinoma	25
Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure: A propensity‐score matched study from AARC	24
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis	24
Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD	24
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis	24
Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36	24
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry	24
Functional rescue of an ABCB11 mutant by ivacaftor: A new targeted pharmacotherapy approach in bile salt export pump deficiency	24
Effects of two personalized dietary strategies during a 2‐year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial	24
The association between etiology of hepatocellular carcinoma and race‐ethnicity in Florida	24
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2	24
MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease	24
Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience	24
Safety of fibrates in cholestatic liver diseases	23
Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity	23
Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes	23
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events	23
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	23
Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation	23
COVID‐19 and viral hepatitis elimination programs: Are we stepping backward?	23
An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia	23
Hepatocyte‐derived MANF alleviates hepatic ischaemia‐reperfusion injury via regulating endoplasmic reticulum stress‐induced apoptosis in mice	22

Association between non‐alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study	22
Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids	22
The role of hepatic lipid composition in obesity‐related metabolic disease	22
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma	22
Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens	22
Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis	22
Normal liver stiffness and influencing factors in healthy children: An individual participant data meta‐analysis	22
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	21
Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use	21
The association of non‐alcoholic fatty liver disease and cardiac structure and function—Framingham Heart Study	21
Liver enzyme variability and risk of heart disease and mortality: A nationwide population‐based study	21
Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry?	21
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis	21
Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets	21
Cellular senescence and hepatitis B‐related hepatocellular carcinoma: An intriguing link	21
Deep learning for noninvasive liver fibrosis classification: A systematic review	21
Hepatoprotective impact of the bile acid receptor TGR5	21
Contrast‐enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta‐analysis	21
COVID‐19 and the liver – Lessons learned	20
Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies	20
A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?	20
Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination	20
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis	20
Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats	20
Chanarin‐Dorfman Syndrome: A comprehensive review	20
Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non‐alcoholic fatty liver disease	20
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients	20
The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population	20
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis	20
Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta‐analysis	20
NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction	19
Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma	19
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	19
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)	19
Liver imaging reporting and data system category M: A systematic review and meta‐analysis	19
Bariatric surgery and the risk of alcohol‐related cirrhosis and alcohol misuse	19
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice	19
High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma	19
Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor	19
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease	19
Paradigm shift in the treatment options of hepatocellular carcinoma	19
The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease	18
Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4	18
Influence of donor and recipient gender on liver transplantation outcomes in Europe	18
Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation	18
m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis	18
Hepatitis B virus‐related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non‐viral risk factors	18
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects	18
Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance	18
Liver transplantation for acute‐on‐chronic liver failure predicts post‐transplant mortality and impaired long‐term quality of life	18
Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease	18
TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy	18
Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study	18
ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes	18
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab	18
Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era	18
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study	17
Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial	17
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications	17
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	17
The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue	17
Interferon‐based treatment of chronic hepatitis D	17
Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study	17
LGR5 induces β‐catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma	17
Evaluation of a serum tumour marker‐based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma	17
YAP‐induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer	17
The global trends and regional differences in incidence of HEV infection from 1990 to 2017 and implications for HEV prevention	17
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	17
Non‐selective beta‐blockers in patients with ascites: The complex interplay among the liver, kidney and heart	17
Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma	17
SPARC inhibition accelerates NAFLD‐associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism	17
The emergency department as a setting‐specific opportunity for population‐based hepatitis C screening: An economic evaluation	17
HCC advances in diagnosis and prognosis: Digital and Imaging	17
Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients	17
New therapies for hepatitis delta virus infection	17
Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review	16
Liver regeneration: Cellular origin and molecular mechanisms	16
Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH	16
Changing clinical management of NAFLD in Asia	16
Integration of miRNA‐regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease	16
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis	16
Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico	16
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles	16
Epidemiology and surveillance of autoimmune hepatitis in Asia	16
New insights in the management of Hepatocellular Adenoma	16
Co‐expression of IL‐7 and PH20 promote anti‐GPC3 CAR‐T tumour suppressor activity in vivo and in vitro	16
Rates and characteristics of SARS‐CoV‐2 infection in persons with hepatitis C virus infection	16
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea	16
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries	16
Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis	16
Exosome‐derived differentiation antagonizing non‐protein coding RNA with risk of hepatitis C virus‐related hepatocellular carcinoma recurrence	16
Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease	16
Sarco‐Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation	16
Quality of life, caregiver burden and mental health disorders in primary caregivers of patients with Cirrhosis	16
Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis	16